InvestSMART

LTR Pharma Ltd (ASX:LTP)

ALERT: Price-sensitive ASX Announcement for LTP
Current share price for LTP : $0.455 -0.055 (-10.78%)+
Announcement
Release
28 Jul 2026 9:01AM
Price at Release
$0.510
Full Release
download
Summary
LTR Pharma Limited's Quarterly Activities Report for the period ending 30 June 2026 highlights significant progress in clinical and commercial operations, notably advancing the SPONTAN® and ROXUS® programs towards a U.S. launch. SPONTAN® Phase II interim results confirmed rapid drug absorption, and ROXUS® secured essential U.S. commercial agreements for its launch. OROFLOW® received ethical approval for clinical testing, expanding its potential therapeutic applications. Financially, the company is robust with A$19.6 million cash on hand and no debt, despite a net operating cash outflow of A$4.4 million, primarily due to research and development expenses.
Key Points
  • LTR Pharma Limited reported its Quarterly Activities Report and Appendix 4C for the period ending 30 June 2026.
  • The company is progressing towards a U.S. commercial launch with key milestones achieved in SPONTAN® and ROXUS® programs.
  • SPONTAN® Phase II interim data shows rapid absorption with a median Tmax of 10 minutes.
  • ROXUS® has secured U.S. commercial agreements for telehealth and pharmacy fulfilment.
  • OROFLOW® received ethics approval for an investigator-initiated clinical study.
  • The company maintains a strong financial position with A$19.6 million in cash and no debt.
  • Net operating cash outflow was A$4.4 million for the quarter.
  • LTR Pharma engaged in research and development expenditures of A$3.8 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.